| CEO Name | Yvonne Greenstreet |
| Nationality | United Kingdom |
| Net Worth Estimation | $50 million |
Yvonne Greenstreet's estimated net worth of $50 million stems largely from her executive compensation, significant stock awards, and equity holdings accrued since joining Alnylam Pharmaceuticals, where she has held key leadership roles including CEO. Her extensive industry experience in biopharmaceuticals, prior senior positions at Pfizer and GlaxoSmithKline, and board memberships also contribute to her financial standing.
Yvonne Greenstreet, CEO of Alnylam Pharmaceuticals, has an estimated net worth of $50,000,000, which is 62.5% of the maximum CEO net worth and 500% of the minimum in the biotechnology sector. Her net worth positions her solidly above the average among biotech CEOs based on the stated range.
Business Category: Biotechnology
Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 80000000 USD
Yvonne Greenstreet Performance in Alnylam Pharmaceuticals
Yvonne Greenstreet, CEO of Alnylam Pharmaceuticals, demonstrates strategic leadership and decisive decision-making in advancing RNAi therapeutics. Under her direction, Alnylam has expanded its pipeline and strengthened global partnerships, driving significant revenue growth and innovation. Her impact is evident in the company's enhanced market position and accelerated product development timelines.
Latest News
Alnylam Pharmaceuticals Reports Strong Growth and Pipeline Progress Under CEO Yvonne Greenstreet
In 2025, Alnylam Pharmaceuticals achieved significant commercial growth with $851 million in Q3 product revenues and strong sales of Amvuttra, driven by expanded use in ATTR-cardiomyopathy. CEO Yvonne Greenstreet highlighted 2024 as a pivotal year with positive HELIOS-B trial results for vutrisiran, positioning the company for continued growth and innovation in RNAi therapeutics targeting rare diseases and beyond.
Source: http://investors.alnylam.com/press-release?id=29381